Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
People who are overweight or who have type 2 diabetes mellitus (T2DM) have higher levels of
certain fats in their blood. The blood vessels and heart of most of these individuals do not
work normally and people with T2DM also have an impaired ability to perform exercise. The
purpose of this study is to use the free fatty acid lowering drug, acipimox, to temporarily
decrease the level of fat in the bloodstream of people with T2DM and observe the
physiological changes to blood vessel function and exercise capacity and insulin sensitivity.
This will help the investigators to understand ways of improving blood vessel function and
the ability to exercise effectively in people who are overweight or have T2DM.
Phase:
N/A
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Pfizer US Department of Veterans Affairs VA Office of Research and Development